Year: 2026

Introduction Building a pharmaceutical brand in India no longer requires owning a manufacturing plant. Pharmaceutical third party manufacturing has emerged as the most accessible, cost-efficient, and strategically powerful model for launching and scaling a pharma business — and it has transformed India’s healthcare industry from within. The Indian pharmaceutical market is expected to reach a value of ₹4,71,295 crores by 2026, and third-party manufacturing is one of the primary engines driving this growth. Whether you are a new entrepreneur entering the healthcare sector, a doctor wanting to launch your own medicine brand, a distributor looking to expand your product portfolio, or an international importer seeking quality Indian medicines — third party manufacturing gives you access to world-class production without the crore-level capital investment of building your own facility. This guide covers everything you need to know about pharmaceutical third party manufacturing in India — how it works, who it is for, what documents are required, how to evaluate a manufacturing partner, and why Salvavidas Pharmaceutical Pvt. Ltd. is the trusted choice for businesses building their pharma brand. What Is Pharmaceutical Third Party Manufacturing? Pharmaceutical third party manufacturing in India is a contractual arrangement in which a pharmaceutical company with licensed manufacturing facilities produces medicines, nutraceuticals, or healthcare products for a third party — typically a brand, distributor, or marketing company that does not own its own manufacturing unit. In simple terms: You own the product brand, marketing rights, and distribution network The manufacturer owns the facility, equipment, licenses, and technical expertise Together, you bring quality pharmaceutical products to market faster and at significantly lower cost than either party could alone This approach is also known as contract manufacturing and has become a common practice in India, where the pharmaceutical landscape is highly competitive and innovation-driven. Who Is Pharmaceutical Third Party Manufacturing For? Third party pharma manufacturing is the right model for a wide range of business profiles: Business Type How Third Party Manufacturing Helps New Pharma Entrepreneurs Launch a medicine brand without factory investment PCD Franchise Businesses Expand product range without manufacturing overheads Doctors & Healthcare Professionals Create proprietary medicine brands under your name Distributors & Wholesalers Add private-label products to your portfolio International Importers Source WHO-GMP certified medicines under your brand Established Pharma Brands Outsource overflow production or new product lines Export-Focused Businesses Access certified Indian manufacturing for global supply Large pharmaceutical manufacturers require additional capacity for in-demand medications. Businesses that offer marketing services aim to serve various markets. Healthcare practitioners, such as doctors or pharmacists, want to establish their own medical labels. Export businesses that appeal to the global market with Indian generic drugs. All of these profiles benefit directly from the third party model. How Does Pharmaceutical Third Party Manufacturing Work? Step-by-Step Process The pharma third-party manufacturing process involves several critical steps. Here is a clear, practical walkthrough: Step 1: Product Selection Start with high-demand, low-competition products. Decide which medicines you want to market — including composition, dosage form (tablet, capsule, syrup, injection, cream), pack size, and target market. Research therapeutic categories where demand is strong and supply gaps exist. Step 2: Choose Your Manufacturing Partner Choosing one out of the list of third party manufacturing pharma companies in India is a very critical business decision. After all, it will ultimately determine the quality of your product and expedite market entry. In this respect, one should give priority only to WHO-GMP-certified facilities that have an established track record. Step 3: Submit Required Documents Both parties exchange business and product documentation — including drug licenses, GST registration, marketing authorizations, and product specifications — to formalize the manufacturing relationship. Step 4: Sign Manufacturing Agreement The U.S. Congress passed the “BIOSECURE Act” restricting federal contracts with certain foreign biotech firms, prompting U.S. pharma companies to shift contracts from China to India — creating a massive tA legal manufacturing agreement is drafted and signed between the company and the third party pharmaceutical manufacturer that outlines the rights and responsibilities of both the parties involved in the third party manufacturing model. Key terms include pricing, MOQs, timelines, packaging specifications, and confidentiality clauses.ailwind for Indian CDMOs as “China Plus One” beneficiaries. Step 5: Raw Material Procurement & Quality Testing The manufacturer sources Active Pharmaceutical Ingredients (APIs) and excipients from approved vendors. In WHO-GMP certified plants, every raw material undergoes strict quality testing before being released for production. Step 6: Manufacturing & In-Process Quality Checks The product is manufactured under supervision and goes through multiple stages of quality testing. Batch Manufacturing Records (BMRs) are maintained throughout the production process. Step 7: Finished Product Testing & Certificate of Analysis The largest segment of India’s CDMO market, covering synthesis and production of Active Pharmaceutical Ingredients for generic and branded drug manufacturers worldwide. Small molecules exhibit clear dominance with a 67.2% share of the total India CDMO market in 2025. Step 8: Packaging & Branding Under Your Label Finished goods are packed under the company’s brand name and delivered to the designated location. Packaging design, foil printing, labeling, and carton artwork are typically provided by the client and executed by the manufacturer. Step 9: Delivery & Distribution Products are shipped to the client’s warehouse, distribution network, or directly to end buyers — depending on the agreed logistics arrangement. Typical Timeline: It usually takes about 8–11 weeks, on average, from the beginning of the documentation to a finished product. Timelines vary based on product complexity and documentation readiness. Key Benefits of Pharmaceutical Third Party Manufacturing Third-party manufacturing offers several significant advantages for pharmaceutical companies. By outsourcing production, companies can tap into the expertise and advanced facilities of established manufacturers, which can result in substantial cost savings and improved efficiency. 1. No Factory Investment Required You do not have to spend crores of rupees on land acquisition, building development, and skilled manpower. Rather, you can employ the knowledge of the best pharma companies that have already been optimizing their supply chain. This way, you can easily turn your high capital expenditure into operational expenses. 2. Faster Market Entry

Introduction The global pharmaceutical industry has fundamentally shifted toward outsourcing — and at the heart of this shift is the contract manufacturing pharmaceutical company, or CDMO (Contract Development and Manufacturing Organization). Rather than building and operating their own manufacturing infrastructure, pharmaceutical companies of all sizes are partnering with specialized contract manufacturers to produce APIs, formulations, biologics, and packaging at scale, speed, and lower cost. India has emerged as the world’s most strategic destination for pharmaceutical contract manufacturing. The India CDMO market was valued at USD 8.52 billion in 2025 and is projected to reach USD 16.53 billion by 2034, growing at a CAGR of 7.39%. Driven by India’s deep generics manufacturing heritage, world-class regulatory compliance, and cost-competitive infrastructure, Indian CDMOs now serve global pharmaceutical companies from startups to multinational innovators. This guide explains exactly what pharmaceutical contract manufacturing is, what services it covers, how to evaluate a CDMO partner, the top companies in India, and why Salvavidas Pharmaceutical Pvt. Ltd. is a trusted choice for businesses seeking a reliable manufacturing partner. What Is a Contract Manufacturing Pharmaceutical Company (CDMO)? A Contract Development and Manufacturing Organization (CDMO) — or Contract Manufacturing Organization (CMO) — is a company that provides pharmaceutical manufacturing services to other pharmaceutical companies on a contractual basis. Rather than the client building their own facility, the CDMO manufactures products on their behalf, using the client’s formula, or developing the formulation and manufacturing it end-to-end. Core Services Offered by a Pharmaceutical Contract Manufacturer: *API Manufacturing — Production of Active Pharmaceutical Ingredients (bulk drugs) *Finished Dosage Form (FDF) Manufacturing — Tablets, capsules, injectables, syrups, topicals *Formulation Development — Creating and optimizing drug formulations for stability and bioavailability Process Development — Scaling laboratory processes to commercial manufacturing *Packaging Services — Primary and secondary packaging, labeling, serialization *Analytical & Regulatory Support — Quality testing, stability studies, regulatory dossier preparation *Clinical Supply Manufacturing — Small-scale production for clinical trials India’s Pharmaceutical Contract Manufacturing Market: Key Numbers (2025–2026) Contract manufacturing services dominate India’s CDMO market with a 53.8% share in 2025, driven by strong demand for API production, finished dosage form manufacturing, and biologics outsourcing. Metric Data India CDMO Market Value (2025) USD 8.52 Billion – USD 25.51 Billion* Projected Market Value (2034–2035) USD 16.53 Billion – USD 71.14 Billion* CAGR (2026–2034) 7.39% – 10.80%* Contract Manufacturing Share 53.8% of total CDMO market Small Molecule Dominance 67.2% of India CDMO market Sterile Injectable CAGR (Global) 9.05% through 2031 Oncology Segment Share 32.15% of global CDMO revenue API Segment Share 51.78% – 54.92% of revenue Range reflects varying estimates across multiple market research sources. India’s CDMO market is driven by a large pool of skilled scientists, cost-effective manufacturing capabilities, and a well-established generic and biosimilars industry. It is expected to grow at a CAGR of 10.80% during 2026–2035 and attain a market value of USD 71.14 billion by 2035. Why India Is the World’s Most Preferred Pharmaceutical Contract Manufacturing Destination 1. Deep Generics Manufacturing Heritage India is the world’s largest producer of generic drugs, accounting for 20% of the worldwide supply by volume and supplying about 60% of the global vaccination demand — well-positioned to meet this demand through its robust CDMO infrastructure. 2. Significant Cost Advantage India’s ability to offer low-cost manufacturing without compromising on quality has positioned it as a preferred destination for pharmaceutical outsourcing. The country benefits from lower labor costs, reduced operational expenses, and economies of scale, making it highly competitive compared to Western countries. 3. Regulatory Alignment with Global Standards India holds more USFDA-approved manufacturing facilities outside the US than any other country. Indian CDMOs’ adherence to international regulatory standards, coupled with their ability to provide end-to-end solutions from research and development to manufacturing, attracts global pharmaceutical companies. 4. “China Plus One” Strategic Advantage The U.S. Congress passed the “BIOSECURE Act” restricting federal contracts with certain foreign biotech firms, prompting U.S. pharma companies to shift contracts from China to India — creating a massive tailwind for Indian CDMOs as “China Plus One” beneficiaries. 5. Government Policy Support India’s Production Linked Incentive (PLI) scheme, the Make in India initiative, and harmonized regulatory standards continue to attract both domestic and foreign investment into pharmaceutical contract manufacturing — reducing barriers and increasing global competitiveness. 6. Skilled Scientific Workforce Indian CDMOs benefit from a long history in generic drug manufacturing, which has shaped a workforce skilled in process optimization, scale-up, and regulatory compliance — now being applied to more advanced services including biologics, cell and gene therapies, and niche formulations. Types of Pharmaceutical Contract Manufacturing Services in India API Contract Manufacturing The largest segment of India’s CDMO market, covering synthesis and production of Active Pharmaceutical Ingredients for generic and branded drug manufacturers worldwide. Small molecules exhibit clear dominance with a 67.2% share of the total India CDMO market in 2025. Finished Dosage Form (FDF) Contract Manufacturing Production of ready-to-dispense pharmaceutical formulations: *Solid orals — Tablets, capsules, sachets *Liquid orals — Syrups, suspensions, dry syrups *Sterile injectables — Ampoules, vials, pre-filled syringes *Topicals — Creams, ointments, transdermal patches *Inhalers — MDIs, dry powder inhalers Biologics & Biosimilar Contract Manufacturing Large molecules/biologics are projected to grow at a 15.26% CAGR, challenging small-molecule dominance — with Indian CDMOs investing in mammalian cell culture, monoclonal antibody production, and single-use bioreactor systems. Third-Party / Private Label Manufacturing Businesses without their own manufacturing infrastructure outsource production under their own brand name. This model is widely used by: *PCD (Propaganda Cum Distribution) pharma franchise businesses *Regional and national pharmaceutical distributors *New pharma brands entering the market without capital-intensive facility investment *International importers and distributors in semi-regulated markets High-Potency API (HPAPI) Manufacturing HPAPIs are projected to grow at an 8.05% CAGR to 2031 — driven by the expansion of oncology drug pipelines requiring specialized containment manufacturing capabilities. How to Choose the Right Contract Manufacturing Pharmaceutical Company Selecting a CDMO partner is one of the most consequential supply-chain decisions a pharmaceutical company will make. Here is the evaluation framework experienced buyers use: 1. Regulatory Certifications Confirm the facility holds WHO-GMP as a

Introduction Among all pharmaceutical dosage forms, sterile injectables carry the highest manufacturing risk and the lowest tolerance for error. Because injectable products bypass the body’s natural defenses and are introduced directly into the bloodstream, muscle, or tissue, even microscopic contamination can cause serious harm. This is why sterile injectable manufacturing is governed by some of the most demanding regulatory and engineering standards in the entire pharmaceutical industry. India has emerged as a global hub for sterile injectable production — combining advanced aseptic processing infrastructure with cost-competitive manufacturing. But not every facility that produces injectables operates at true sterile manufacturing standards. For hospitals, distributors, and pharmaceutical companies sourcing parenteral products, understanding what genuine sterile manufacturing requires is essential to choosing the right partner. This guide goes deep into the technical foundation of sterile injectable manufacturing in India — aseptic processing, cleanroom classifications, fill-finish technology, sterility assurance — and explains why Salvavidas Pharmaceutical Pvt. Ltd. approaches sterile manufacturing with the rigor this category demands. What Makes a Product “Sterile”? A pharmaceutical product is classified as sterile when it is completely free from viable microorganisms. For injectable (parenteral) products, regulatory bodies set an extremely high bar: an injectable can only be classified as sterile once it achieves a probability of microbial contamination of less than one in one million units — known as the Sterility Assurance Level (SAL). Achieving this level of assurance is not a single step — it is the result of an entire manufacturing ecosystem engineered around contamination prevention, from raw material handling through final packaging. Why Sterile Injectable Manufacturing Is Different from Other Dosage Forms Drug products delivered via the parenteral, ophthalmic, inhaled, or otic route present an increased risk of infection or harm because they bypass many of the body’s natural defenses. This is precisely why regulatory authorities mandate that such products be supplied only as sterile preparations. Unlike tablets or capsules — which can often be terminally sterilized after final packaging — many modern injectable products (biologics, monoclonal antibodies, certain proteins and enzymes) are heat-sensitive or otherwise cannot withstand terminal sterilization. These products must instead be manufactured using aseptic processing, where every component — the drug substance, the container, and the closure — is sterilized separately and then combined in a controlled environment that prevents any contamination from entering the final product. This requirement is what makes injectable manufacturing facilities the most sophisticated and challenging pharmaceutical facilities to design, build, and operate. Understanding Cleanroom Classifications in Sterile Manufacturing Aseptic processing and sterile fill-finish operations take place in cleanrooms specifically designed to control the flow of personnel, materials, and equipment to minimize contamination risk. Cleanrooms are organized in a cascading design, where air quality increases progressively as you move closer to the most critical zone of the facility. Grade / ISO Class Description Use in Sterile Manufacturing Grade A / ISO 5 Critical zone — highest air quality, Class 100 Aseptic filling, stopper/vial handling, open product exposure Grade B / ISO 7 Background environment for Grade A zone Surrounding area for the aseptic core Grade C / ISO 8 Controlled processing areas Preparation of solutions, less critical processing Grade D Supporting/gowning areas Personnel gowning, material staging, non-sterile prep The flow of personnel, materials, and equipment typically begins in supporting, lower-grade areas — where gowning and non-sterile preparation occur — and proceeds inward toward the Grade A critical zone, where the actual aseptic filling takes place. The Sterile Fill-Finish Process Sterile fill-finish is the final and most critical step in injectable manufacturing — where the drug product is filled into its final containers (vials, ampoules, pre-filled syringes, or cartridges) under strictly controlled aseptic conditions. Key stages include: 1. Component Sterilization Because the active ingredient remains in powder form until reconstitution, dry syrups avoid the degradation that occurs when moisture-sensitive drugs are stored in liquid form for long periods — making them ideal for distribution across long supply chains and varied climates. Strong Market Growth The global dry syrup market — which includes pediatric pharmaceuticals and antibiotic treatments — is expected to grow at a steady CAGR through 2028, driven by the increased occurrence of respiratory infections and other treatable conditions in children. India’s broader cold and cough remedies market alone is projected to reach significant value by 2025–2026, reflecting strong sustained demand. Widespread OTC and Prescription Use Dry syrups span both prescription antibiotic therapy and over-the-counter (OTC) categories like multivitamins and cough remedies, giving manufacturers a broad and resilient market. Why India Leads in Dry Syrup Manufacturing 1. Cost-Effective Production Vials, stoppers, and other container components are sterilized independently — often via dry heat depyrogenation or autoclaving — before entering the aseptic core. 2. Sterile Filtration The drug solution is passed through sterilizing-grade filters (typically 0.22 micron) within an ISO 5 environment, using closed, single-use filtration systems to minimize human contact with the product. 3. Aseptic Filling The sterile solution is filled into pre-sterilized containers under Grade A conditions. Modern facilities increasingly use isolator technology and Restricted Access Barrier Systems (RABS) to physically separate operators from the critical processing zone — significantly reducing the single greatest source of contamination risk: human presence. 4. Stoppering & Capping Containers are sealed immediately after filling, still within the controlled aseptic environment, to prevent any post-fill contamination. 5. Lyophilization (Where Applicable) For freeze-dried (lyophilized) injectables, partially stoppered vials are transferred to sterile freeze-dryers, where the product is dried under vacuum before full stoppering — all within the aseptic boundary. 6. Environmental Monitoring Continuous monitoring of particulate counts, microbial levels, temperature, humidity, and pressure differentials throughout the process ensures the cleanroom maintains its required classification at all times. Aseptic Processing Technologies Used in Modern Sterile Facilities This is the foundational quality benchmark. Always confirm current certification status directly with the manufacturer. Technology Function Isolator Systems Physically isolates the aseptic core from operators using glove-port access, drastically reducing contamination risk RABS (Restricted Access Barrier Systems) Provides a barrier between operators and the critical zone while allowing more flexible access than full isolators Vapor-Phase Hydrogen